Skip to content

Clinical study of thoracic paravertebral nerve block with different approaches guided by ultrasound for the treatment of thoracodorsal herpes zoster pain.

Clinical study of thoracic paravertebral nerve block with different approaches guided by ultrasound for the treatment of thoracodorsal herpes zoster pain.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082392
Enrollment
Unknown
Registered
2024-03-28
Start date
2024-03-28
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain

Interventions

Group T:The medication solution A is injected at the level between the transverse process and the midpoint of the pleura.
Group MTP:The medication solution B is injected at the level between the transverse process and the midpoint of the pleura.
Group ESP:The medication solution B is injected at the fascial plane between the transverse process and the erector spinae muscle.
Group SCTL :The medication A is injected below the costotransverse ligament

Sponsors

Huishan District People's Hospital of Wuxi
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.18 to 80 years old patients with acute thoracodorsal herpes zoster neuralgia (within 1 month), VAS score above 6; 2.Patients agree to bear the risk of thoracic paravertebral block and consent to treatment. 3.Patients must understand the research process and evaluation, agree to participate in this trial, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals who have difficulty understanding the mechanism of thoracic paravertebral block or those who refuse the procedure. 2. Known allergies to any medications such as ropivacaine, compounded betamethasone injection, lidocaine injection, etc. 3. Patients who are unable to tolerate the thoracic paravertebral block procedure. 4. Patients with concurrent infections in respiratory system, urinary system, or other related organs. 5.Patients with moderate to severe liver or kidney dysfunction (ALT/AST > 80U/L; creatinine clearance < 10ml/min). 6.Patients with serious immunological disorders. 7. Individuals with local puncture site infection, injury, or pregnancy. 8. Patients currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Absolute values of T lymphocyte subsets;NRS;

Secondary

MeasureTime frame
CRP;the doses of oral drugs;

Countries

China

Contacts

Public ContactDan Li

Huishan District People's Hospital of Wuxi

li-dan984@163.com+86 150 6189 3066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026